FDA plans to take steps to enhance the collection and availability of clinical trial data on demographic subgroups.
By: Margaret A. Hamburg, M.D.Margaret A. Hamburg, M.D., is Commissioner of the U.S. Food and Drug Administration August 20, 2014, Today...
Astrazeneca and Mitsubishi Tanabe Pharma Corporation announce research collaboration in diabetic nephropathy
AstraZeneca and Mitsubishi Tanabe Pharma Corporation (MTPC) today announce a three-year research collaboration in the area of diabetic nephropathy. The aim of the research...
AstraZeneca announces positive top-line results from the Phase III programme of CAZ-AVI in patients with complicated intra-abdominal infections (cIAI)
CAZ-AVI treated patients with cIAI as effectively as meropenem CAZ-AVI also treated cIAI patients infected with ceftazidime-resistant bacteria as effectively as meropenem ...
ABBOTT JOINS FORCES WITH U.S. DEPARTMENT OF DEFENSE TO DEVELOP PORTABLE BLOOD TESTS FOR EVALUATING CONCUSSIONS
Abbott and the United States Department of Defense today announced a collaboration with the intent to develop portable blood tests to help evaluate potential...
FDA Grants Tentative Approval For Lilly And Boehringer Ingelheim’s Basaglar™ (Insulin Glargine Injection)
The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is indicated to improve glycemic control in...
EISAI Files Lenvatinib in Europe for People With Radioiodine-Refractory Thyroid Cancer
FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. MEDIA
EMA accepts accelerated review for orphan therapy in hard-to-treat thyroid cancer
Eisai announces today that it has filed...
Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a pivotal clinical pharmacokinetic (PK)...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...